Skip to main content

Metastasis Brain NEO212-01

Status: Open to Enrollment
Email Us To Enroll

Study Details

View study details on clinicaltrials.gov.

Locations

  • San Francisco
  • Palo Alto
  • Roseville

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

An Open-label Phase 1/2 Dose Finding, Safety and Efficacy Study of Oral NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Uncontrolled Brain Metastasis in Patients With Select Solid Tumors

Akanksha Sharma, M.D.
Akanksha Sharma, M.D.
Principal investigator
View Profile

You're leaving our site

The website you have selected is an external one located on another server. This website may contain links to third party sites. These links are provided for convenience purposes and are not under the control of Sutter Health. Do you wish to continue?